Glypican-3/GPC3 Protein, Cynomolgus (HEK293, His)

GPC3 is a member of the heparan sulfate proteoglycans (HSPGs), and attaches to the cell surface by a glycosylphosphatidylinositol anchor. GPC3 is overexpressed in hepatocellular carcinoma (HCC) and can be used as a tumor marker for HCC. Membrane GPC3 can interact with several growth factors to promote the binding of growth factors to their receptors. GPC3 can form a complex with Wnt and activates Wnt signaling, leading to the HCC growth. In addition, GPC3 is also involved in the pathogenesis of Simpson-Golabi-Behmel overgrowth syndrome, regulates cell growth, regulates embryonic and fetal development^[1][2][3]. Glypican-3/GPC3 Protein, Cynomolgus (HEK293, His) is the recombinant Cynomolgus-derived Glypican-3/GPC3 protein, expressed by HEK293 , with C-6*His labeled tag.

GPC3 is a member of the heparan sulfate proteoglycans (HSPGs), and attaches to the cell surface by a glycosylphosphatidylinositol anchor. GPC3 is overexpressed in hepatocellular carcinoma (HCC) and can be used as a tumor marker for HCC. GPC3 plays a role in liver carcinogenesis^[1]. Specifically, Membrane GPC3 can interact with several growth factors (eg: Wnt, Hedgehogs, bone morphogenetic factors, and FGF) to promote the binding of growth factors to their receptors. GPC3 can form a complex with Wnt and activates Wnt signaling, leading to the HCC growth^[2].
In addition, GPC3 can regulate cell growth. GPC3 is highly expressed in mesodermal embryonic tissues, and the deletion of the GPC3 gene is involved in the pathogenesis of Simpson-Golabi-Behmel overgrowth syndrome. The interaction of GPC3 with IGF2 can reduce IGF2-mediated growth in vivo, which indicates that GPC3 negatively regulates embryonic and fetal development. Besides, GPC3 is a negative transcriptional regulator and tumor suppressor that inhibits the growth of breast, ovary, and lung cancer cells^[2][3].
GPC3 has a cleavage site between Arg358 and Ser359, and can be cleaved by Furin protease^[2].

Cynomolgus

HEK293

C-6*His

XP_005594665.1 (Q25-H559)

102137748  [NCBI]

Partial

QPPPPPPDATCHQVRSFFQRLQPGLKWVPETPVPGSDLQVCLPKGPTCCSRKMEEKYQLTARLNMEQLLQSASMELKFLIIQNAAVFQEAFEIVVRHAKNYTNAMFKNNYPSLTPQAFEFVGEFFTDVSLYILGSDINVDDMVNELFDSLFPVIYTQLMNPGLPDSALDINECLRGARRDLKVFGNFPKLIMTQVSKSLQVTRIFLQALNLGIEVINTTDHLKFSKDCGRMLTRMWYCSYCQGLMMVKPCGGYCNVVMQGCMAGVVEIDKYWREYILSLEELVNGMYRIYDMENVLLGLFSTIHDSIQYVQKNAGKLTTTIGKLCAHSQQRQYRSAYYPEDLFIDKKVLKVAHVEHEETLSSRRRELIQKLKSFISFYSALPGYICSHSPVAENDTLCWNGQELVERYSQKAARNGMKNQFNLHELKMKGPEPVVSQIIDKLKHINQLLRTMSVPKGRVLDKNLDEEGFESGDCGDDEDECIGGSGDGMMKVKNQLRFLAELAYDLDVDDVPGNNQQATPKDNEISTFHNLGNVH

Approximately 30-31 kDa & 38-40 kDa & 65-80 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.22 μm filtered solution of PBS, 5% trehalose, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. /biology-dictionary/hepg2-cell.html  [Content Brief]